Novel mavacamten had a big impact on quality of life in obstructive hypertrophic cardiomyopathy, according to a secondary analysis of the EXPLORER-HCM trial.

The cardiac myosin inhibitor improved Kansas City Cardiomyopathy Questionnaire (KCCQ) overall summary score by 9.1 points more than that seen with placebo over 30 weeks (mean 14.9 vs 5.4 points, P<0.001 for difference). A 5-point change in score is considered clinically significant.

Similar advantages were seen across all KCCQ subscores, reported John Spertus, MD, MPH, of Saint Luke's Mid America Heart Institute and the University of Missouri-Kansas City, at the virtual American College of Cardiology meeting and simultaneously in The Lancet.

Read the full Medpage Today article: Mavacamten Boosts Quality of Life in Hypertrophic Cardiomyopathy

Read more >

Related Content

Person, Hair, Nurse, Face, Female, Word
Nicole's story

"What we do is so vital. We have so much power as nurses." Nicole Roberson, Registered Nurse, Neuroscience ICU, Saint Luke's Hospital of Kansas City

Read more >
Person, Doctor, Clothing, Apparel, Lab Coat, Coat, Face, Nurse
Deb's story

Deb Day, Registered Nurse · Anderson County Hospital "I am a Saint Luke's Nurse.  Nurses are the lifeblood of Saint Luke’s compassionate care, and the life-changing work they do is...

Read more >
Apparel, Clothing, Coat, Lab Coat, Person, Doctor
Danielle's story

"You get those rare moments that you're reminded why you went into this field, and it makes everything so much better." Danielle Hammontree, Certified Family Nurse Practitioner, Saint Luke’s East Hospital

Read more >